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A series of 60 gastric endocrine tumors comprised 44 body-fundus argyrophil carcinoids, of
which 23 arose in a background of hypergastrinemia and type A chronic atrophic gastritis
(A-CAG), mainly with histologic patterns suggestive of an autoimmune process. Only 22
percent (compared with 19 percent of 58 tumor-free A-CAG cases) of 36 carcinoids and 21
percent of 19A-CAG carcinoids investigated hadHelicobacterpylori (HP) colonization, against
50 percent of 14 CAG-associated neuroendocrine carcinomas or mixed endocrine-exocrine
tumors, 84 percent of 150 cases with early gastric cancer (p < 0.001 versus carcinoids), mostly
with B- or AB-type CAG, 76 percent of 97 tumor-free AB-CAG, and 95 percent of 151
tumor-free B-CAG cases. Secondary hypergastrinemia and local mechanisms activated by
chronic autoimmune gastritis are among factors involved in the pathogenesis of relatively
indolent CAG-associated carcinoids, whereas active HP gastritis in cooperation with environ-
mental carcinogens may likely cause more severe epithelial transformation, leading to ordinary
cancer and, possibly, to neuroendocrine carcinomas or mixed endocrine-exocrine tumors.
The association between gastric body-fundus carcinoids and autoimmune body-
fundus (type A) chronic atrophic gastritis (CAG) with hypergastrinemia is well
documented [1-5]. The recent detection of Helicobacterpyloni (HP) antibodies in
serum ofelderly people with type A CAG [6] as well as the progressive evolution of
some antrum-body (type AB) pangastritis into A-type CAG [7] suggest that end-
stage HP-related type A CAG may also contribute to carcinoid development. In
addition, there have been reports of carcinoids arising in non-CAG gastric mucosa,
either with hypergastrinemia and multiple endocrine neoplasia/Zollinger-Ellison
syndrome (MEN/ZES) [8] orwithout hypergastrinemia [4,9-111.
The association of CAG or CAG-related intestinal metaplasia (IM) with gastric
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cancer of "intestinal" (i.e., glandular) type is well documented [12-14]. Follow-up
studies have outlined the increased cancer risk inherent to CAG and IM [15],
although intestinal phenotypes were not more frequent in CAG/IM associated
glandular cancers than in CAG/IM unrelated diffuse cancers [16,17]. In addition,
both serological prospective [18,19] and histological retrospective studies [20,21]
have found HP infection, with resultant chronic gastritis, to be positively associated
with gastric cancer, either ofintestinal or diffuse histology.
In this paper, non-tumor mucosa from patients with and without gastric carci-
noids, neuroendocrine carcinomas, orearlycancers hasbeen investigated fordistinc-
tive patterns of tumor-associated gastritis. Attention specifically focused on HP
colonization and gastritis activity, atrophy, or topography as possible factors in
tumorigenesis.
MATERIALS AND METHODS
Histologic material and clinical records of all the 60 gastric endocrine tumors
(mean age, 52 years; 32 males, 28 females) available in the files ofour departments
due to personal observation or consultation were reinvestigated. Histologic sections
from tumor tissue and non-tumor mucosa were stained with hematoxylin-eosin,
Grimelius' silver impregnation for argyrophil cells, periodic acid-Schiff(PAS)-alcian
blue pH 2.5, high-iron diamine (HID), and periodic acid-concanavalin A (PACO-
NA) techniques for mucins, as well as Giemsa stain for Helicobacterpylori [17,22].
Immunoperoxidase tests for chromogranin A, sterotonin, gastrin, somatostatin,
pancreatic polypeptide, enteroglucagon, epithelial membrane antigen (EMA), pep-
sinogen II, Ml antigen ofgastric surface mucin, CAR-5 intestinal antigen, HLA-DR
antigen, L26 B lymphocyte antigen, and UCHL1 T-lymphocyte antigen were carried
out as reported elsewhere [8,17,21,23,24].
Non-tumor mucosa from a surgical series of 150 early gastric cancers (EGCa;
mean age, 63.2 years), an endoscopic series of 1,177 unselected tumor-free patients
(mean age, 53.7 years), and 58 endoscopic tumor-free A-CAG were systematically
investigated for HP and gastritis status according topreviously reported criteria [24].
The EGCa series was collected during the years 1979-1991 in the Pavia and Varese
sections of our department, while the unselected non-tumor series included all the
patients undergoing endoscopy at the Endoscopic Unit ofPavia II Medical Clinic in
the period 1987-1991 with diagnosis of active (228 cases) or healed (269) peptic
ulcer, non-ulcer dyspepsia (631), or various non-gastric symptoms (49). The 58
A-CAG cases resulted from the addition of all the 42 cases observed in Varese,
during theyears 1979-1991, to the 16 cases found amongthe Pavia unselected series.
The chi-squared test was used for statistical analysis.
RESULTS
Gastntis andEndocrine Tumors
TumorHistology The 60 cases of gastric endocrine tumors were classified, as
reported in Table 1, based on their histology (Fig. 1) and on previously reported
criteria [1-5,25,26]. They included 44 carcinoids (mean age, 51 years), nine neuroen-
docrine carcinomas (NEC, also called small-cell carcinomas, intermediate grade;
mean age, 64), three of these with co-existing carcinoid, one gastrinoma, and six
mixed endocrine-exocrine tumors (two combined carcinoid/early cancer, one com-
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TABLE 1
Relationship Between Gastritis Status, HP Colonization, and Co-Existing Tumor
HP status
Mucosal
Pathology n Tumor Disease n +/Total S





AB-CAG 5 Carcinoid/EGCa 1 1/1
Carcinoid/mucinousCa 1 0/1 50
NEC 3 1/2
CAG, type 7 Carcinoid 3 1/1
not assessed NEC 3 1/2
Carcinoid/NEC/ChorCa 1 0/1
HG + MEN/ZES 8 Carcinoid 8 2/7
20
None 10 Carcinoid, sporadic 10 1/8
1 Gastrinoma 1 1/1
Endocrine tumors, total 60 15/49 31
Chronic 150 EGCa, glandular 64/86 74
gastritisa EGCa, diffuse 46/46 100
EGCa, mixed 16/18 89
A-CAG 58 None 11/58 19
AB-CAG 97 None 74/97 76
B-CAG 151 None 143/151 95
Non-atrophic 790 None 711/790 90
gastritis
HP: Helicobacterpylori; CAG: chronic atrophic gastritis; NEC: neuroendocrine carcinoma; HG +/-
MEN/ZES: hypertrophicgastropathywith (seven) orwithout (one) provenmultiple endocrine neoplasia/
Zollinger-Ellison syndrome; EGCa: early gastric cancer; MucinousCa: mucinous carcinoma, ChorCa:
chorioncarcinoma 80 percent ofwhich was CAG, B or AB type
bined carcinoid/tubular adenoma, one adenocarcinoid, one composite carcinoid/
mucinous carcinoma, and one composite carcinoid/NEC/chorioncarcinoma).
Detailed information on the clinicopathologic profile of the tumors has been
reported elsewhere [26].
All carcinoids were histologically well differentiated, intensely chromogranin
A-immunoreactive, argyrophilbut not argentaffin, thusfullfilling the criteria for their
diagnosis asenterochromaflin-like (ECL)-cell argyrophil carcinoids [2-5,9,11,25,26]. They
arose in the fundus (sometimes involvingcardial mucosa), corpus, or transition between
corpus and antrum, especially in the angular region.
Neuroendocrine carcinomas differed from carcinoids in showing immature, ana-
plastic cells with abundant mitoses, scarce reactivity for secretory granule markers
(chromogranins, argyrophilia, hormones), and relatively abundant immunostaining
for cytosolic endocrine markers such as neuron-specific enolase (NSE) or protein
gene product (PGP) 9.5, as well as for the non-endocrine marker epithelial mem-
brane antigen (EMA). An intimate admixture ofcarcinoid and NEC growths inside
the same tumorwasfound onlyin twocases, possiblysuggesting anorigin ofthe NEC
component from anaplastic change of a pre-existing carcinoid. One of these two
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;A t J_Z4o,FIG. 1. Gastric argyrophil carcinoid ad-
ffi 9 < mixed with hyperplasticgrowth of mature
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tumors, however, the carcinoid/NEC/chorioncarcinoma, had the histologic pattern
of a highly malignant, complex tumor of unknown histogenesis. The remaining two
composite tumors showed intimate admixtures ofwell-differentiated endocrine cells
and either frankly carcinomatous mucous-secreting cells (carcinoid/carcinoma) or
well-differentiated, mildly atypical mucopeptic cells reacting with pepsinogen II
antibodies andthePACONAtestforgastricglandsmucin(adenocarcinoid) [10,22,23].
In addition, close association of carcinoid with apparently hyperplastic growth of
foveolar cells was frequently observed (Fig. 1).
Associated Gastritis The histology of non-tumor gastric mucosa, with special
reference to gastritis status and colonization byHelicobaterpylori, has been outlined
in Table 1. Forty-one of the 60 tumors (68.3 percent), including 26 of the 44 (59
percent) carcinoids, and all NECs and mixed tumors, showed some kind of CAG in
non-tumor mucosa. The remaining 19 cases (18 carcinoids and one gastrinoma)
arose in gastritis-free or non-atrophic (less than 30 percent gland atrophy) gastritis
mucosa, either with (eight cases) or without (ten cases) hypertrophic gastropathy
due to hypergastrinemia. In 29 cases, CAG was restricted to corpus-fundus mucosa
(type A); in five, it involved both antral and corpus-fundus mucosa (typeAB); and in
seven, the topographic type was not assessed due to insufficient material available.
Among 19 type A CAG associated with carcinoids investigated, only four (21
percent) had HP colonization, against seven of the remaining 14 (50 percent) CAG
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cases showing a variety of tumors and CAG types (Table 1). Intestinal metaplasia
was detected in corpus mucosa of 30 of 49 (61 percent) endocrine tumors investi-
gated, including 21 of 35 (60 percent) carcinoids, 27 of 33 (82 percent) CAG-
associated tumors, and 17of19 (89 percent) A-CAGcarcinoids,with mean extension
of metaplastic mucosa in positive cases of about 20-30 percent. In antral mucosa,
intestinal metaplasia was consistently found only in the few caseswith AB CAG.
Five of ten carcinoid patients with HP-negative type A CAG in whom pertinent
hematologic investigations were performed showed pernicious anemia (PA). In
another HP-negative A-CAG case showing corpus-fundus carcinoids and NEC,
megaloblastic anemia developed five years after proximal gastric resection. Only one
of 11 HP-positive CAG cases (seven of which were type A) with various kinds of
tumors showed PA. In addition to type A CAG, this patient also had circulating
anti-parietal cell antibodies aswell as autoimmune thyroiditis. The class II histocom-
patibility antigen HLA-DR was abundantly expressed in non-endocrine epithelia of
both HP-negative and HP-positive CAG mucosa. No HLA-DR antigen was detected
in adjacent endocrine growths, however, either hyperplastic or dysplastic and
neoplastic.
HP-negativeA-CAG cases withPA (Fig. 2)were characterizedbydiffuse, total, or at
least subtotal atrophy of acidopeptic glands, with disappearance of mature parietal
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and chief cells coupled with hyperplasia of immature, basophilic, PGI-, PGII-, and
PACONA-positive mucous neck cells (so-called pseudopyloric metaplasia) [22].
Deep, multifocal pyloric-type metaplasia (PGII- and PACONA-positive, but PGI-
negative) with or without gastrin-immunoreactive G cells, more or less extensive
intestinal metaplasia ofsmall intestine (I) type, and more or less prominent foveolar
hyperplasia with or without hyperplastic polyps were also found. Abundant inflam-
matory cells were observed in the lamina propria of deep and mid mucosa, with
relative prevalence oflymphocytes (both B and T cells) over plasma cells, especially
around immature mucous-neck glands with evidence of epithelial aggression and
damage. Neutrophilic granulocytes were found only occasionally at sites of non-HP
bacterial colonization of superficial mucosa. The antropyloric mucosa was either
entirely normal or with mild, superficial, inactive gastritis and no epithelial damage
ormetaplastic change.
HP-positive CAG cases (Fig. 3) showed an abundance of plasma cells in the
superficial half of the corpus fundus mucosa, with or without few neutrophilic
granulocytes, abundance oflymphocytes (especially B cells in follicles, both B and T
cells diffusely in the lamina propria) in the deep half, often coupled with fairly
abundant eosinophils, mast cells, andmacrophages. All 11 caseshad HPcolonization
of inflamed corpus fundus mucosa, while only two of nine cases tested had antral
mucosa colonization. Surviving areas or small groups of acidopeptic glands with
mature parietal and chiefcells, in addition to mucous-neck and transitional mucous-
neck/chief cells [27], were found in all cases, especially in proximal fundus mucosa.
Immature mucous-neckcell hyperplasiawas lessprominent,while intestinalmetapla-
sia, partly ofincomplete (II or III) type, was more abundant than in HP-negative PA
cases. Antropyloric mucosa of cases with HP-positive corpus fundus CAG was
characterized by various grades of chronic gastritis, from atrophic with intestinal
metaplasia (AB-type CAG, two cases) to HP-positive interstitial-follicular type with
relatively scarce activity and abundant plasma cells and B lymphocytes (one case), or
HP-negative type with mild inflammation, often associated with myofibroblast
proliferation in the mild and deep lamina propria (six cases). The latter pattern
probably results from healingofantritis coupled with progression ofatrophic corpus
gastritis, a relatively frequent observation in older patients with chronic HP gastritis
[6,7,24].
Gastritis andEarly Cancer
Asoutlined in Table 1, ofthe 150earlygastriccancersinvestigated, 86 (57percent)
formed glandular structures (glandular or "intestinal" type), 46 (31 percent) were
non-structured tumor growths (diffuse type), and 18 (12 percent) were mixed
glandular/diffuse. HP colonization of non-tumor mucosa was detected in 126 cases
(84 percent, p < 0.001 versus the 49 endocrine tumors, the 35 pure carcinoids, as
well as the 19 A-CAG carcinoids investigated), including all diffuse tumors, 64 of86
(74 percent) glandular, and 16 of 18 (89 percent) mixed tumors. Corpus fundus
mucosa showed HP in 80 percent ofcases against 60 percent ofantropyloric mucosa.
Gastritis activity was prominent at the foveolar-neck level of pyloric and/or corpus
mucosa in the majority of cases.
CAG was found in 82 percent of the cases, of which 46 percent was B type
(restricted to the antrum), 34 percent AB type, and 2 percent A type, while
non-atrophic or mildly atrophic gastritis accounted for the remaining 18 percent.
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FIG. 3. a. HP-positive type A chronic
atrophic gastritis with a surviving islet of
mature acidopepticglands surrounded by
heavy lymphoid infiltrates. Hematoxylin-
eosin, x160. b. HP colonization of
damaged superficial-foveolar epithelium
in a non-atrophic area ofacidopeptic mu-
cosa, from a composite NEC-carcinoid
case. Giemsa stain, x600.
This gastritis pattern differed significantly from that of endocrine tumors as a whole
or of carcinoids, especially with regard to type A CAG excess among endocrine
tumors/carcinoids (p < 0.001) and type B CAG excess (p < 0.001) among cancer
patients. Among cancer patients, HP was detected in 91 percent of type B CAG, 75
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percent of type AB, 50 percent of type A, and 100 percent of common gastritis, with
slightly higher incidence in the antral mucosa for the last group and more obvious
predominance in the corpus mucosa for the other groups.
As many as 88 percent ofcases showed intestinal metaplasia in peritumor mucosa,
80 percent in antral mucosa, and 30 percent in corpus mucosa. Type III (sulfomucin-
positive) intestinal metaplasia was detected in 56 percent of cases. Intestinal
metaplasia as a whole and type III metaplasia were three to five times more
abundant in stomachs with glandular cancer than in those with diffuse cancer.
Tumor-Free Gastritis
Unselected Series HP was found in 931 of 1,177 endoscopic patients (79.1
percent), including 27 of49 asymptomatic subjects (55.1 percent), 462 of631 patients
with non-ulcer dyspepsia (73.2 percent), 71 of 76 active gastric ulcers (93.4 percent),
32 of 39 healed gastric ulcers (82.1 percent), 132 of 138 active duodenal ulcers (95.7
percent), and 194 of 230 healed duodenal ulcers (84.3 percent).
CAG was present in 264 patients (22.4 percent), including 12.8 percent type B, 8.2
percent type AB, and 1.4 percent type A, while 790 subjects (67.1 percent) had
non-atrophic gastritis and 123 (10.5 percent) gastritis-free mucosa. The incidence of
CAG as awhole was significantly lower (p <0.001) than that ofcancer, carcinoid, or
endocrine tumor patients. By itself, the ten to 11 years' greater age of cancer
patients, with respect to tumor-free patients, would correspond to a marginal,
non-significant increase of CAG incidence from 22 to 28 percent in the latter
population. A-CAG incidence was obviously higher (p <0.001) in endocrine tumor
or carcinoid (but not cancer) cases than in tumor-free cases, while the incidence of
both B- and AB-CAG was higher in cancer than in tumor-free cases (p < 0.001),
and thatofB-CAGwas lower in endocrine tumor than in tumor-free cases (p < 0.05).
HP colonization was found in 95 percent oftype B, 76 percent oftype AB (p < 0.001
versus type B), 31 percent of type A (p < 0.001 versus type B as well as versus type
AB), 90 percent of non-atrophic gastritis (p <0.001 versus type AB as well as type
A), and none of gastritis-free cases. No significant difference was observed with
respect to corresponding gastritis groups ofcancer or endocrine tumor patients.
Intestinal metaplasia (mostly typeI) was observed in 25 percent of antral biopsies
and 7 percent of corpus biopsies. Both figures were significantly lower (p < 0.001)
than those observed in cancer patients as a whole or in glandular cancer cases.
Combined antrum + corpus incidence of IM was near 0 percent in gastritis-free
cases, 20 percent (extension about 5 percent) in common non-atrophic gastritis, 63
percent (antral extension about 30 percent) in type B, 70 percent (extension about
20-30 percent) in type AB, and 81 percent (corpus extension about 30 percent) in
type A CAG.
Selected A-CAG Cases Among the 58 A-CAG cases, 11 (19 percent) showed
HP colonization, which involved corpus mucosa in all cases and antral mucosa in
seven cases. Ten of the 11 HP-positive cases showed a pattern of corpus gastritis
characterized by residual acidopeptic glands, abundant plasma cells, granulocytes,
and intestinal metaplasia (present in seven cases; mean extension, 30 percent of the
mucosa), thus mimicking the HP-positive A-CAG associated with endocrine tumors,
apart from increased activity. Forty-three of the 47 HP-negative cases showed a
severe diffuse pattern of oxyntic gland atrophy with lack of mature acidopeptic
glands, abundantpyloric/pseudopyloric metaplasia (coveringabout 50percentofthe
glandularcompartment, as against 20-30 percent in the formergroup), fewerplasma
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cells and granulocytes, and less extensive intestinal metaplasia (present in 20 of the
43 cases, covering less than 10 percent of the mucosa as a mean), thus mimicking
"autoimmune" A-CAG of endocrine tumor patients. Pernicious anemia was de-
tected in 11 of the 35 cases (31 percent) from which hematologic data were available.
All PA cases were HP-negative and showed the "autoimmune" type of A-CAG with
diffuse gland atrophy.
DISCUSSION
Most gastric endocrine tumors investigated were from body-fundus or transitional
body-antrum mucosa (95 percent) and showed morphological patterns of argyrophil
carcinoids (73 percent), usually with ECL cells as a prominent component [4,10,26].
Twenty-three of 44 (52 percent) argyrophil carcinoids arose in a background of
severe corpus fundus (type A) atrophic gastritis, coupled with achlorhydria-related
hypergastrinemia, while three (7 percent) showed CAG of type not assessed.
Interestingly, hypergastrinemia has been observed in all A-CAG patients with
carcinoids so far investigated [2-5,11,26], suggesting that both advanced A-CAG and
the resulting hypergastrinemia are essential in the development of body fundus
argyrophil carcinoids with very low malignant potential [26]. A crucial role of
hypergastrinemia in the genesis of gastric argyrophil ECL-cell carcinoids has been
conclusively shown in aged achlorhydric rats [28]. Circulating anti-parietal cell
antibodies impairing acidopeptic gland maturation and function [29-31] as well as
HLA-DR-mediated autoimmune aggression to non-endocrine gastric epithelia, with
special reference to mucous-neck cells, may account for the severe atrophy of
acidopeptic glands in autoimmune type A CAG, often associated with pernicious
anemia. The incomplete pattern ofgland atrophy (frequently leaving patchy areas of
surviving glands with mature parietal and chief cells) that we observed in most
HP-positive A-CAG cases may explain their failure to develop pernicious anemia.
Composite tumors showing an intimate admixture of endocrine and exocrine cells,
as in two ofour cases, suggest that some body fundus endocrine tumors may originate
from neoplastic transformation of pluripotent epithelial stem cells that retain some
capacity ofdual, endocrine, and non-endocrine differentiation [32]. Stem-cell growth
seems also involved in the histogenesis of neuroendocrine carcinomas which, in
addition to undifferentiated and poorly differentiated endocrine cells, often show
more or less prominent non-endocrine glandular or even squamous components
[10,33].
The co-existence oftopographically separate endocrine and exocrine tumors (as in
three of our cases) can be explained by their sharing of some risk factor or condition.
Indeed, pernicious anemia patients with A-type CAG are known to be at increased
risk for both carcinoids and cancer [34]. Gastrin, a growth factor for ECL cells [35]
and related tumors [28], as well as for epithelial stem cells in the oxyntic mucosa [35],
might have a role in the pathogenesis ofboth endocrine and exocrine tumors arising
in the corpus fundus, possibly by acting in combination with other factors released
locally during chronic inflammation, such as some prostaglandins [36,37] and lympho-
kines [38-40] known to modulate both endocrine and exocrine gastric epithelia. This
hypothesis would also explain the frequent, intimate association offoveolar hyperpla-
sia, known to be promoted by prostaglandin E2 (PGE2), and underlying carcinoids.
As for ordinary gastric cancer, it must be recalled that oxyntic gland cell lines are
only seldom found in such tumors, where gastrin-independent intestinal and pyloric
lines largely predominate [16,17,23,41]. In fact, hypergastrinemia seems to inhibit
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rather than stimulate pyloric carcinogenesis, providing mucosal contact with acid
juice is preserved [43], while its role in intestinal carcinogenesis is controversial
[44,45].
The high incidence of HP colonization in stomachs with early cancer (84 percent,
p < 0.001 versus carcinoids) was in the same range as that found in simultaneously
investigated gastric (93 percent) or duodenal (96 percent) ulcers, two well-
established HP-related diseases, and in non-ulcer dyspepsia (73 percent), also
known to be in part related to HP gastritis [24], while it differed significantly
(p < 0.001) from that of subjects free of gastric symptoms (55 percent). Thus, our
colonization findings further support the hypothesis suggested by serologic studies,
combined with epidemiologic [46] and prospective investigations [18,19], that HP
infection may represent a major risk factor for gastric cancer. The fact that diffuse
cancer, unrelated to intestinal metaplasia [13,21], has even higher HP colonization
(100 percent versus 74 percent, p < 0.001) and HP-related risk [19] than does
metaplasia-related "intestinal" cancer suggests that, in addition to the carcinoge-
netic pathway leading from CAG to intestinal metaplasia and dysplasia [12-14],
another mechanism alsocontributes tothe HP-related risk. It seemspossible thatthe
active inflammation observed at foveolar neck level of EGCa patients causes
oxidative stress to generative zone epithelia as well as increased proliferation and
topographicexpansion ofthe epithelial stemcells, up to superficial epithelia exposed
to environmental carcinogens [21]. Direct interaction of lumen-contacting cells
retaining proliferative potential and endoluminal carcinogens has already been
shown to be crucial in rat carcinogenesis [47].
HP incidence was very low in both CAG-associated (21 percent) and CAG-
unrelated (20 percent) carcinoids, and similar to that oftumor-free A-type CAG (19
percent). Moreover, carcinoid-associated gastritis was usually inactive or poorly
active, even when HP-positive. As discussed above, other factors, unrelated to HP
and intestinal metaplasia, mustbe involved in carcinoid pathogenesis.
In conclusion, it seems likely that, despite the occurrence of HP in a small
proportion of stomachs bearing endocrine tumors, active HP gastritis has little role
in the pathogenesis ofgastricargyrophil carcinoids. The hypergastrinemia-producing
type A CAG, be it purely autoimmune or end stage of HP gastritis, when found in
association with carcinoids, is as a rule inactive; that is, devoid ofgranulocytes. On
the contrary, active HP gastritis seems to have a major role in the pathogenesis of
gastric cancer, leading preferentially to glandular cancer in abackground oftype AB
or B CAG, coupled with extensive intestinal metaplasia (especially of type III), and
to diffuse cancer in the presence of type B CAG or non-atrophic gastritis without
type III metaplasia, with orwithout moderately developed type I metaplasia.
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